MESOBLAST LTD.

In News

Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rally - Proactive Investors

Proactive Investors - Jul 21, 2025

Jefferies Downgrades Mesoblast Limited - Depositary Receipt () (MESO) - MSN

MSN - Jul 19, 2025

Healthcare Stocks Move in Pre-Market Session: Telomir Pharmaceuticals, Mesoblast, and More - AInvest

AInvest - Jul 19, 2025

Mesoblast (MESO) Reports Initial Sales Success of Ryoncil | MESO Stock News - GuruFocus

GuruFocus - Jul 18, 2025

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds? - Yahoo Finance

Yahoo Finance - Jan 31, 2025

Mesoblast Limited Announces New Substantial Holder - TipRanks

TipRanks - May 02, 2025

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga

Benzinga - Jul 01, 2025

US FDA approves Mesoblast's cell therapy for graft-versus-host disease - Reuters

Reuters - Dec 19, 2024

Mesoblast stock soars after reporting first Ryoncil sales - Investing.com Australia

Investing.com Australia - Jul 18, 2025

What analysts say about Mesoblast Limited Depositary Receipt stock - Unprecedented growth rates - Autocar Professional

Autocar Professional - Jul 20, 2025

Why Mesoblast shares can keep storming higher - MSN

MSN - Jul 21, 2025

Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires - Yahoo Finance

Yahoo Finance - Mar 10, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.